Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech patent grant

Anixa Australian Patent Breast Cancer Vaccine

Analysis based on 6 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026

Sentiment
5
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The patent grant modestly strengthens Anixa's intellectual property position and long-term commercialization optionality for its breast cancer vaccine, but it does not change near-term revenue or clinical timelines, so the market reaction was muted with the stock slightly lower. For the broader biotech sector the news is immaterial, as it concerns a single clinical-stage company's IP estate rather than a sector-wide development.

biotechnology pharmaceuticals

Anixa Biosciences announced that Australia — Australian Government issued Patent Number 2020221280, a composition-of-matter patent titled Vaccine Adjuvants and Formulations, covering its breast cancer vaccine technology in Australia through 2040. The technology is exclusively licensed from Cleveland Clinic, where it was developed, and the co-inventors are Dr. Ron Johnson and the late Dr. Vincent Tuohy. The Australian patent complements Anixa's existing patent estate in the United States, Europe, China, and Japan, strengthening its global intellectual property position and its ability to pursue regulatory approvals, partnerships, and commercialization. The vaccine targets human alpha-lactalbumin, a retired protein aberrantly expressed in certain breast cancers, aiming to prime the immune system against tumor formation, particularly in aggressive forms such as triple-negative breast cancer. A recently completed Phase 1 trial at Cleveland Clinic, funded by the United States — United States Department of Defense, met all major primary endpoints, was safe and well tolerated, and generated protocol-defined immune responses in more than 74% of participants. No preventive breast cancer vaccine is currently approved anywhere in the world. Anixa's broader pipeline includes liraltagene autoleucel, an ovarian cancer immunotherapy developed with H. Lee Moffitt Cancer Center & Research Institute. Cleveland Clinic is entitled to royalties and other commercialization revenues under the exclusive license. Anixa shares traded down about 2 percent following the announcement.

stock
Anixa is the central actor, receiving the Australian composition-of-matter patent through 2040 for its breast cancer vaccine and expanding its global IP estate. The grant supports future regulatory and partnering prospects, though the stock traded down about 2 percent on the day.
Importance 100.0 Sentiment 10.0
priv
Cleveland Clinic developed the vaccine technology, exclusively licensed it to Anixa, and is entitled to royalties and other commercialization revenues. Its researchers are the named co-inventors on the patent.
Importance 70.0 Sentiment 5.0
govactor
Australia — Australian Government issued Patent Number 2020221280, the regulatory action at the center of this event, granting protection in Australia through 2040.
Importance 60.0 Sentiment 0.0
cnt
Australia is the jurisdiction granting the patent, providing exclusive protection for the vaccine technology through 2040 in a market with rising breast cancer incidence.
Importance 40.0 Sentiment 0.0
govactor
The Department of Defense funded the Phase 1 trial at Cleveland Clinic that met all major primary endpoints and showed immune responses in more than 74 percent of participants.
Importance 30.0 Sentiment 0.0
per
As Chairman and CEO of Anixa, Amit Kumar commented that the patent strengthens the global foundation for the breast cancer vaccine and supports potential partnerships with larger pharmaceutical companies.
Importance 25.0 Sentiment 0.0
cnt
The United States is Anixa's primary clinical development market and part of its existing patent portfolio, complementing the new Australian protection.
Importance 20.0 Sentiment 0.0
cnt
China is one of the international markets where Anixa already holds patent protection, complementing the new Australian patent.
Importance 10.0 Sentiment 0.0
cnt
Japan is one of the international markets where Anixa already holds patent protection, complementing the new Australian patent.
Importance 10.0 Sentiment 0.0
per
Dr. Ron Johnson of Cleveland Clinic is a named co-inventor on the patent covering the vaccine adjuvants and formulations.
Importance 10.0 Sentiment 0.0
per
The late Dr. Vincent Tuohy of Cleveland Clinic is a named co-inventor on the patent covering the vaccine adjuvants and formulations.
Importance 10.0 Sentiment 0.0
Australia related ↔ United States
Australia related ↔ China
Australia related ↔ Japan
United States strategic rival ↔ China The United States perceives China as a strategic rival, actively implementing sanctions and export controls, while addre
United States ally ↔ Japan The United States considers Japan a cornerstone defense ally and a vital economic partner in the Indo-Pacific, with exte
China rivals ↔ Japan China views Japan as a strategic rival, actively challenging its stance on Taiwan and territorial claims. China has impo
China related ↔ Ron Johnson
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.